4.7 Article

Diabetes, Alzheimer disease, and vascular dementia A population-based neuropathologic study

期刊

NEUROLOGY
卷 75, 期 13, 页码 1195-1202

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f4d7f8

关键词

-

资金

  1. Academy of Finland [120676, 129395]
  2. Swedish Council for Working Life and Social Research
  3. AstraZeneca
  4. Unilever
  5. Bayer Schering Pharma
  6. Boehringer Ingelheim
  7. Pfizer Inc.
  8. Eli Lilly and Company
  9. Merck Serono
  10. Novartis
  11. Sanofi-Aventis
  12. Takeda Pharmaceutical Company Limited
  13. Schering-Plough Corp.
  14. Novo Nordisk, DeveloGen AG
  15. Leiras
  16. Ranbaxy Laboratories Limited
  17. Merck Sharp Dohme
  18. Academy of Finland (AKA) [129395, 120676, 129395, 120676] Funding Source: Academy of Finland (AKA)

向作者/读者索取更多资源

Objective: To investigate the relation of diabetes to dementia, Alzheimer disease (AD), and vascular dementia (VaD), through analyses of incidence, mortality, and neuropathologic outcomes in a prospective population-based study of the oldest old. Methods: The Vantaa 85+ study included 553 residents living in the city of Vantaa, Finland, and aged >85 years on April 1, 1991. Survivors were reexamined in 1994, 1996, 1999, and 2001. Autopsies were performed in 291 persons who died during the follow-up (48% of total population). Diabetes was assessed according to self-report, medical record of physician-diagnosed diabetes, or use of antidiabetic medication. Macroscopic infarcts were identified from 1-cm coronal slices of cerebral hemispheres, 5-mm transverse brainstem slices, and sagittal cerebellum slices. Methenamine silver staining was used for beta-amyloid, methenamine silver-Bodian staining for neurofibrillary tangles, and modified Bielschowsky method for neuritic plaques. Cox proportional hazards and multiple logistic regression models were used to analyze the association of diabetes with dementia and neuropathology, respectively. Results: Diabetes at baseline doubled the incidence of dementia, AD, and VaD, and increased mortality. Individuals with diabetes were less likely to have beta-amyloid (hazard ratio [HR] [95% confidence interval (CI)] was 0.48 [0.23-0.98]) and tangles (HR [95% CI] 0.72 [0.39-1.33]) but more likely to have cerebral infarcts (HR [95% CI] 1.88 [1.06-3.34]) after all adjustments. Conclusion: Elderly patients with diabetes develop more extensive vascular pathology, which alone or together with AD-type pathology (particularly in APOE epsilon 4 carriers) results in increased dementia risk. Neurology (R) 2010; 75: 1195-1202

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据